NASDAQ: ASND
Ascendis Pharma A Stock

$170.44+3.86 (+2.32%)
Updated Apr 30, 2025
ASND Price
$170.44
Fair Value Price
N/A
Market Cap
$10.34B
52 Week Low
$111.09
52 Week High
$171.34
P/E
-25.06x
P/B
-93.94x
P/S
21.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$378.79M
Earnings
-$393.84M
Gross Margin
87.8%
Operating Margin
-75.13%
Profit Margin
-104%
Debt to Equity
-12.16
Operating Cash Flow
-$319M
Beta
0.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ASND Overview

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ASND's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ASND
Ranked
#48 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ASND news, forecast changes, insider trades & much more!

ASND News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASND scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ASND is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ASND is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ASND's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ASND due diligence checks available for Premium users.

Valuation

ASND price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-25.06x
Industry
-162.28x
Market
29.18x

ASND price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-93.94x
Industry
4.45x

ASND's financial health

Profit margin

Revenue
$181.2M
Net Income
-$40.1M
Profit Margin
-22.1%
ASND's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ASND's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.2B
Liabilities
$1.3B
Debt to equity
-12.16
ASND's short-term assets ($1.11B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASND's short-term assets ($1.11B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASND's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASND's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$90.8M
Investing
-$400.0k
Financing
$90.6k
ASND's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ASND vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ASNDC$10.34B+2.32%-25.06x-93.94x
EXELA$10.96B+1.56%21.75x4.88x
MRNAF$11.01B+2.59%-3.08x1.01x
INCYA$12.13B+3.69%216.07x3.31x
BMRNA$12.15B+0.65%28.31x2.15x

Ascendis Pharma A Stock FAQ

What is Ascendis Pharma A's quote symbol?

(NASDAQ: ASND) Ascendis Pharma A trades on the NASDAQ under the ticker symbol ASND. Ascendis Pharma A stock quotes can also be displayed as NASDAQ: ASND.

If you're new to stock investing, here's how to buy Ascendis Pharma A stock.

What is the 52 week high and low for Ascendis Pharma A (NASDAQ: ASND)?

(NASDAQ: ASND) Ascendis Pharma A's 52-week high was $171.34, and its 52-week low was $111.09. It is currently -0.52% from its 52-week high and 53.43% from its 52-week low.

How much is Ascendis Pharma A stock worth today?

(NASDAQ: ASND) Ascendis Pharma A currently has 60,689,487 outstanding shares. With Ascendis Pharma A stock trading at $170.44 per share, the total value of Ascendis Pharma A stock (market capitalization) is $10.34B.

Ascendis Pharma A stock was originally listed at a price of $18.83 in Jan 28, 2015. If you had invested in Ascendis Pharma A stock at $18.83, your return over the last 10 years would have been 805.15%, for an annualized return of 24.64% (not including any dividends or dividend reinvestments).

How much is Ascendis Pharma A's stock price per share?

(NASDAQ: ASND) Ascendis Pharma A stock price per share is $170.44 today (as of Apr 30, 2025).

What is Ascendis Pharma A's Market Cap?

(NASDAQ: ASND) Ascendis Pharma A's market cap is $10.34B, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ascendis Pharma A's market cap is calculated by multiplying ASND's current stock price of $170.44 by ASND's total outstanding shares of 60,689,487.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.